Abstract: The invention provides isolated nucleic acids molecules, designated HYDL-1 nucleic acid molecules, which encode novel hydrolase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing HYDL-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an HYDL-1 gene has been introduced or disrupted. The invention still further provides isolated HYDL-1 proteins, fusion proteins, antigenic peptides and anti-HYDL-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: Nucleic acid compositions and polypeptides encoding a red-shifted form of firefly luciferase are provided. These red-shifted luciferases are characterized by spectrum of light emission having detectable emissions at 610 nm (luc610), preferably a primary peak at 610 nm. The nucleic acid compositions find use in various systems as a reporter gene, and are of particular interest for use as a reporter with in vivo systems, because of the efficient transfer of red light through tissues. The red-shifted luciferase may be combined in such assays with luciferases emitting at other spectra, in order to monitor multiple processes simultaneously.

Abstract: A protein complex containing 245 kDa and 35 kDa components, designated RAFT1 and RAFT2 (for Rapamycin And FKBP12 Target) interacts with FKBP12 in a rapamycin-dependent manner. This interaction has the pharmacological characteristics expected from the observed in vivo effects of rapamycin: it occurs at low nanomolar concentrations of rapamycin and is competed by excess FK506. Sequences (330 amino acids total) of tryptic peptides derived from the affinity purified 245 kDa RAFT1 reveals striking homologies to the predicted products of the yeast TOR genes, which were originally identified by mutations that confer rapamycin resistance in yeast. A RAFT1 cDNA was obtained and found to encode a 289 kDa protein (2550 amino acids) that is 43% and 39% identical to TOR2 and TOR1, respectively.

Abstract: A gene which contains the nucleotide sequence shown in SEQ ID NO:1 from nucleotide 671 to nucleotide 6295 or a nucleotide sequence which can be obtained therefrom by substitution, insertion or deletion of up to 30%, preferably up to 10%, particularly preferably up to 20%, especially preferably up to 5%, of the nucleotides, and whose gene product has the enzymatic activity of an adenylate cyclase, and its use.

Abstract: The present invention provides isolated I&kgr;B kinases that regulate NF&kgr;B gene transcription that lack both a leucine zipper like &agr;-helix domain and helix-loop-helix domain. Also provided are the amino acid sequences of these kinases and the nucleotide sequence encoding these kinases, and other related protein and nucleic acid molecules.

Abstract: A method for treating silage to enhance aerobic stability by inhibiting growth of yeast strains associated with spoilage of silage is disclosed. The method comprises treating silage or feed with a composition comprising killer yeast strains, or the antimicrobial components produced thereby. According to the invention, strains of Saccharomyces exiguus have been purified and isolated which are nontoxic, safe, do not assimilate lactate and which improve aerobic stability of silage, are disclosed. Portions of these strains have been sequenced to further characterize the invention.

Abstract: This invention relates to the chemical design and production of peptides, peptide structure and three dimensional conformation was assessed using NMR, circular dichroisin and pulsed field gradient NMR. In addition, this invention relates to peptides produced by these methods and to methods for using the peptides.

Abstract: This invention relates to a novel human deoxyribonuclease, referred to as LS-DNase, that is relatively resistant to inhibition by actin, as compared to human DNase I. The invention provides nucleic acid sequences encoding LS-DNase, thereby enabling the production of LS-DNase by recombinant DNA methods in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of LS-DNase.

Abstract: Novel ATPase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ATPase-like proteins, the invention further provides isolated ATPase-like fusion proteins, antigenic peptides, and anti-ATPase-like antibodies. The invention also provides ATPase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ATPase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: Described and claimed are compounds of the formula wherein: Y is a polypeptide, R1 is bonded to the N-terminus of Y and is hydrogen or a branched or linear, substituted or unsubstituted, C1-21 alkyl, alkene, or alkyne group, R2 is a side chain of a naturally occuring amino acid, and X is Such compounds are useful as haptens and immunogens for the elicitation of antibodies which catalytically enhance the rate of formation or hydrolysis of primary amide bonds. Also described and claimed are methods employing the compounds and antibodies.

Abstract: The invention provides methods and compositions relating to an I&kgr;B kinase, IKK-&agr;, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-&agr; encoding nucleic acids or purified from human cells. The invention provides isolated IKK-&agr; hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-&agr; genes, IKK-&agr;-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

Abstract: The present invention relates to Subtilisin DY variants having a modified amino acid sequence of wild-type Subtilisin DY amino acid sequence, the wild-type amino acid sequence comprising a first loop region, a second loop region, a third loop region, a fourth loop region, a fifth loop region and a sixth loop region; wherein the modified amino acid sequence comprises different amino acids than that occurring in wild-type Subtilisin DY (i.e., substitution) at specifically identified positions in one or more of the loop regions whereby the Subtilisin DY variant has decreased adsorption to, and increased hydrolysis of, an insoluble substrate as compared to the wild-type Subtilisin DY. The present invention also relates to DNA sequences encoding such Subtilisin DY variants. The present invention also relates to compositions comprising such Subtilisin DY variants for cleaning a variety of surfaces.

Abstract: The present invention relates to novel nucleic acid sequences which, upon expression in a procaryotic or eucaryotic cell, code for a polypeptide having an elevated specific xylose isomerase activity compared to the wildtype Thermus thermophilus xylose isomerase. They are selected from a) nucleic acid sequences shown in SEQ. ID. No 1; b) the complementary strand of the sequence defined in (a) above; c) nucleic acid sequences which hybridize to the sequences defined in (a) or (b) above; d) nucleic acid sequences which, but for the degeneracy of the genetic code, would hybridize to the sequences defined in (a), (b) or (c) above and which code for the same polypeptide as those defined in (a), (b) or (c) above. The present invention further provides a process of producing ethanol from xylose containing materials comprising contacting cells that express such nucleic acid sequences and novel modified xylose isomerases that advantageously can be applied in the production of fructose syrups.

Abstract: The present invention provides a human tumor suppressor (HKALL) and polynucleotides which identify and encode HKALL. The invention also provides expression vectors and host cells, agonists, antibodies, or antagonists. The invention provides methods for treating diseases associated with expression of HKALL.

Abstract: A recombinant DNA is constructed by using a toluene monooxygenase gene isolated from Ralstonia eutropha strain TB64 and employed to provide the transformant which can express toluene monooxygenase useful for cleaning of aqueous media such as drain and waste water containing halogenated aliphatic hydrocarbon compounds or aromatic compounds, for remediation of soil polluted with such compounds, and cleaning of air (gas phase) polluted with volatile organic chlorine compounds.

Abstract: The present invention relates, in general, to a method of producing L-amino acids comprising culturing altered bacterial cells having increased amounts of NADPH as compared to unaltered bacterial cells whereby L-amino acids yields from said altered bacterial cells are greater than yields from unaltered bacterial cells. The invention also relates to a gene encoding phosphoglucoisomerase.

Abstract: Novel carbonyl hydrolase mutants derived from the amino acid sequence of naturally-occurring or recombinant non-human carbonyl hydrolases and DNA sequences encoding the same. The mutant carbonyl hydrolases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant carbonyl hydrolase to encode the substitution, insertion or deletion of one or more amino acids in the amino acid sequence of a precursor carbonyl hydrolase. Such mutants have one or more properties which are different than the same property of the precursor hydrolase.

Abstract: The present invention relates to a nucleic acid molecule which codes for the cephalosporin acetylesterase from Bacillus subtilis ATCC 6633 (DSM 11909), vectors and host cells which comprise such a nucleic acid molecule, a process for the recombinant preparation of cephalosporin acetylesterase from B. subtilis ATCC 6633 (DSM 1 1909) using said nucleic acid molecule, and a process for preparing 3-deacetylcephalosporin compounds.

Abstract: A recombinant RNA-dependent RNA polymerase of hepatitis C virus (r-HCV-RDRP) coding DNA was cloned and expressed yielding active enzyme in vitro. The r-HCV-RDRP can include up to 20 added amino acids and up to nine deleted or substituted amino acids at the NH2-terminus of the encoded amino acid sequence. The invention provides method to solubilize r-HCV-RDRP from a host cell lysate and purified r-HCV-RDRP. Methods for screening for inhibitors of r-HCV-RDRP in vitro, for making stably transfected mammalian cells expressing r-HCV-RDRP and for in vivo testing of r-HCV-RDRP inhibitors in vivo are disclosed. The invention provides antibodies to r-HCV-RDRP and methods for detecting antibodies to HCV-RDRP in serum of human patients.

Abstract: The present invention relates to subtilisin Carlsberg variants having a modified amino acid sequence of wild-type subtilisin Carlsberg amino acid sequence, the wild-type amino acid sequence comprising a first loop region, a second loop region, a third loop region, a fourth loop region, a fifth loop region and a sixth loop region; wherein the modified amino acid sequence comprises different amino acids than that occurring in wild-type subtilisin Carlsberg (i.e., substitution) at specifically identified positions in one or more of the loop regions whereby the subtilisin Carlsberg variant has decreased adsorption to, and increased hydrolysis of, an insoluble substrate as compared to the wild-type subtilisin Carlsberg. The present invention also relates to the genes encoding such subtilisin Carlsberg variants. The present invention also relates to compositions comprising such subtilisin Carlsberg variants for cleaning a variety of surfaces.